ES 
EN 
DE 
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
Blog
The number of PubMed publications on synthetic peptides grows by several to more than ten percent each year. BPC-157 pentadecapeptide, Thymosin Beta-4 fragments, GLP-1 receptor agonists, and nootropic peptides from the Russian pharmacology school ? each of these directions has its own literature, research models, and methodological limitations. This blog organizes that knowledge by category.
Who is this blog for? For people evaluating peptides through analysis of available literature. For academic researchers, biohackers, lifestyle medicine physicians, and pharmacists looking for references to support patient discussions.
A research comparison of MK-677 and ipamorelin, focusing on GHS-R1a signaling, selectivity, administration route, human evidence and WADA status.
A research comparison of MK-677, GHRP-2 and GHRP-6, including receptor action, molecular class, administration route, evidence and WADA status.
A research comparison of cardarine and ostarine (MK-2866), two distinct compound classes with different targets, evidence bases and safety signals.
GHRP-2 and GHRP-6 are the two most frequently mentioned peptides from the family of growth hormone-releasing peptides – short, synthetic molecules that in research models stimulate the pituitary gland to release growth hormone. Both come from the same generation of secretagogues discovered by Cyril Y. Bowers’ team, and both act through the same receptor, the GHS-R1a ghrelin receptor. The record varies: in […]
YK-11 vs ostarine — a scientific comparison. Ostarine: clinical trials up to phase III. YK-11: in vitro only, no human data. See the key differences. Research reagents (RUO).
YK-11 — a steroidal partial androgen receptor agonist. The follistatin/myostatin pathway. Literature review. Cell-culture data only. Research reagent (RUO).
RAD-140 vs ostarine — a scientific comparison of two SARMs: research phase, model organism, selectivity and safety signals. Research reagents (RUO).
RAD-140 (Testolone): AR mechanism, neuroprotection and experimental oncology in models, a hepatotoxicity (DILI) signal and WADA status. Research reagent (RUO).
Andarine (S4) vs ostarine (MK-2866) — a scientific comparison of two SARMs: research phase, models, selectivity and safety signals. Research reagents (RUO).
Andarine (S4, GTx-007) in research: SARM mechanism, preclinical rodent data, the vision profile (xanthopsia) and WADA S1 status. Research-reagent profile (RUO).
LGD-4033 vs ostarine (MK-2866) — a scientific comparison of two SARMs: research phase, models, tissue selectivity and safety signals. Research reagents (RUO).
LGD-4033 (Ligandrol): SARM mechanism, phase I data in healthy volunteers, safety signals (testosterone suppression, a DILI case report) and WADA S1 status. Research reagent (RUO).
This material is intended for educational purposes only and describes the current state of knowledge in cell biology. It does not constitute medical advice, a
This article is for educational purposes only and presents the state of scientific knowledge on mitochondrial biology and the processes of ageing. It does not
The ageing of an organism is a progressive, multi-level accumulation of molecular and cellular damage that leads to a gradual loss of tissue function. Contemporary
This article is educational in nature and constitutes a review of the scientific literature on the molecular pathways studied in the biology of cellular ageing.
This article is educational in nature and constitutes a review of the published scientific literature on telomere biology and biomarkers of cellular ageing. It describes
This article is educational in nature and constitutes a review of the published scientific literature. A substantial part of the data cited comes from animal
MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a mitochondrial-derived peptide composed of 16 amino acids, encoded not in the cell nucleus but
Six Knowledge Areas
Regenerative peptides and neuropeptides: molecular mechanisms
The broadest section of the catalog. It covers tissue-regeneration peptides (BPC-157, TB-500, GHK-Cu, PEG-MGF), neuropeptides (Semax, Selank, DSIP), and melanocortin peptides (PT-141, Melanotan II). Each article starts with the discovery context and then moves to the molecular mechanism: signaling pathways, target receptors, and pharmacokinetics.
SARMs ? selective androgen receptor modulators
A class of non-peptide compounds with high affinity for the androgen receptor, intensively studied in the context of anabolic clinical protocols. This section discusses pharmacological mechanisms, phase I and phase II clinical data, and comparisons of research profiles across individual compounds.
Laboratory practice ? reconstitution, storage, analysis
A procedural section. It explains how to correctly reconstitute a lyophilized reagent, which water to use, how to maintain solution stability in the cold chain, and how to interpret the analytical document attached to each batch. Materials for people running laboratory protocols.
Metabolism and incretins ? GLP-1 peptides
A section focused on one of the fastest-growing pharmacological classes of the 21st century: GLP-1 receptor agonists and their derivatives. It covers semaglutide (first generation, well established in clinical trials) and retatrutide (a GLP-1/GIP/glucagon tri-agonist, currently in phase III clinical trials).
Anti-aging and longevity ? peptides in aging research
The fifth area: peptides in the context of cellular aging processes, telomere regulation, neuroplasticity in later adulthood, and social-axis hormones (oxytocin). This section maintains methodological rigor ? highlighting that most evidence still comes from animal models or short-term human trials.
Quality, safety, and regulation
An analytical and regulatory section. It explains how HPLC and MS methods work, which standards apply to research-peptide suppliers in Europe, what to look for when evaluating a source, and what legal status research peptides have in the Polish regulatory system.
